{"id":45288,"date":"2022-06-21T09:01:49","date_gmt":"2022-06-21T07:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/"},"modified":"2022-06-21T09:01:49","modified_gmt":"2022-06-21T07:01:49","slug":"iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/","title":{"rendered":"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nAgreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design<b> <\/b>\n<\/li>\n<li>\nCollaboration leverages Iktos\u2019 capabilities in machine learning and AI and Zealand expertise in peptide drug discovery\n<\/li>\n<\/ul>\n<p>PARIS&#8211;(BUSINESS WIRE)&#8211;Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A\/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.\n<\/p>\n<p>\nIktos\u2019 AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. Iktos has recently diversified its R&amp;D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.\n<\/p>\n<p>\nZealand Pharma A\/S has a track record of successfully inventing and developing novel peptide-based drugs. This success is based on the extensive experience in improving the therapeutic characteristics of peptides. Zealand Pharma has a keen interest in expanding its computational chemistry toolbox to include AI and machine learning based approaches for the design of novel therapeutic peptides (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zealandpharma.com%2F&amp;esheet=52752063&amp;newsitemid=20220621005033&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.zealandpharma.com%2F&amp;index=1&amp;md5=4e68e731b0e405b109e05cfa62415ad5\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.zealandpharma.com\/<\/a>).\n<\/p>\n<p>\nUnder the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos\u2019 generative modelling technologies and expertise in machine learning and AI.\n<\/p>\n<p>\n\u201cWe are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery\u201d commented Yann Gaston-Math\u00e9, President and CEO of Iktos. \u201cWe look forward to working with Zealand\u2019s experienced R&amp;D team to build leading\/state of the art peptide generative and predictive modelling technology in the field of peptides &#8211; a new area for Iktos.\u201d\n<\/p>\n<p class=\"bwalignc\">\n<b># # #<\/b>\n<\/p>\n<p>\n<b><i>About IKTOS<\/i><\/b>\n<\/p>\n<p>\nIncorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&amp;D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya\u2122. Iktos is also developing Spaya\u2122, a synthesis planning software based upon Iktos\u2019s proprietary AI technology for retrosynthesis. Iktos has recently diversified its R&amp;D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.\n<\/p>\n<p>\n<b>More information on: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iktos.ai%2F&amp;esheet=52752063&amp;newsitemid=20220621005033&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.iktos.ai%2F&amp;index=2&amp;md5=dd5cc279d9a52cd085033a8717374e30\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.iktos.ai\/<\/a><\/b>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Contact information :<\/b> Yann Gaston-Math\u00e9 (CEO) \u2013 <a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;&#x6f;:c&#111;&#110;&#x74;&#x61;&#x63;t&#64;&#105;&#107;&#x74;&#x6f;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">contact&#64;ikto&#115;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design Collaboration leverages Iktos\u2019 capabilities in machine learning and AI and Zealand expertise in peptide drug discovery PARIS&#8211;(BUSINESS WIRE)&#8211;Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A\/S (Nasdaq: ZEAL) (CVR-no. 20045078), &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45288","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design Collaboration leverages Iktos\u2019 capabilities in machine learning and AI and Zealand expertise in peptide drug discovery PARIS&#8211;(BUSINESS WIRE)&#8211;Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A\/S (Nasdaq: ZEAL) (CVR-no. 20045078), ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-21T07:01:49+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design\",\"datePublished\":\"2022-06-21T07:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/\"},\"wordCount\":493,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/\",\"name\":\"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-06-21T07:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/","og_locale":"en_US","og_type":"article","og_title":"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design - Pharma Trend","og_description":"Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design Collaboration leverages Iktos\u2019 capabilities in machine learning and AI and Zealand expertise in peptide drug discovery PARIS&#8211;(BUSINESS WIRE)&#8211;Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A\/S (Nasdaq: ZEAL) (CVR-no. 20045078), ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-21T07:01:49+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design","datePublished":"2022-06-21T07:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/"},"wordCount":493,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/","url":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/","name":"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-06-21T07:01:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iktos-and-zealand-pharma-to-develop-artificial-intelligence-technology-for-peptide-drug-design\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45288"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45288\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}